📊 CVM Key Takeaways
Investment Thesis
CEL SCI Corp is a pre-revenue or near-zero revenue biotech company with severe operational losses and negative cash flow, indicating it is not yet generating meaningful commercial activity. The company is burning cash at approximately $4M annually with only $6.3M in cash reserves, suggesting a finite runway of less than 2 years without additional capital raises. The distorted profitability ratios (positive margins despite negative absolute results) and persistent negative returns on equity and assets indicate a company in early-stage development with significant execution risk.
CVM Strengths
- Adequate liquidity position with current ratio of 1.39x and $6.3M cash on hand
- Moderate leverage with debt-to-equity of 0.51x providing some financial flexibility
- Recent insider activity (4 Form 4 filings in 90 days) may indicate management confidence
CVM Risks
- Severe cash burn of $4M annually with limited runway (less than 2 years at current burn rate)
- Revenue near zero (-$87.8K) with no evidence of commercial traction or product viability
- Persistent negative operating cash flow and lack of path to profitability visible in current operations
- Company operates in highly competitive biological products sector with long development timelines and high failure rates
- Negative returns on equity (-49.1%) and assets (-23.9%) indicate shareholder value destruction
Key Metrics to Watch
- Cash runway and burn rate trends (critical for survival)
- Revenue growth trajectory and any clinical trial milestones
- Operating cash flow improvement and path to profitability
- Capital raises and dilution (essential given cash burn)
- R&D spending efficiency and product pipeline advancement
CVM Financial Metrics
💡 AI Analyst Insight
The 4,581.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
CVM Profitability Ratios
CVM vs Healthcare Sector
How CEL SCI CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CVM Balance Sheet & Liquidity
CVM 5-Year Financial Trend
5-Year Trend Summary: CEL SCI CORP's revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-15.31 indicates the company is currently unprofitable.
CVM Growth Metrics (YoY)
CVM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2017 | $51.8K | -$3.8M | $-1.29 |
| Q2 2017 | $34.4K | -$4.9M | $-0.03 |
| Q3 2011 | $30.9K | -$601.1K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CVM Capital Allocation
CVM SEC Filings
Access official SEC EDGAR filings for CEL SCI CORP (CIK: 0000725363)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVM
What is the AI rating for CVM?
CEL SCI CORP (CVM) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVM's key strengths?
Adequate liquidity position with current ratio of 1.39x and $6.3M cash on hand. Moderate leverage with debt-to-equity of 0.51x providing some financial flexibility.
What are the risks of investing in CVM?
Severe cash burn of $4M annually with limited runway (less than 2 years at current burn rate). Revenue near zero (-$87.8K) with no evidence of commercial traction or product viability.
What is CVM's revenue and growth?
CEL SCI CORP reported revenue of $-87.8K.
Does CVM pay dividends?
CEL SCI CORP does not currently pay dividends.
Where can I find CVM SEC filings?
Official SEC filings for CEL SCI CORP (CIK: 0000725363) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVM's EPS?
CEL SCI CORP has a diluted EPS of $-0.68.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.